Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CGEN
CGEN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CGEN News
Compugen Appoints New Independent Director
4d ago
PRnewswire
HC Wainwright Initiates Buy on Jade Biosciences with $25 Price Target
Jan 07 2026
Benzinga
Compugen Agrees with AstraZeneca to Monetize Future Royalties of Rilvegostomig
Dec 17 2025
PRnewswire
Compugen Secures $65 Million Upfront Payment in AstraZeneca Deal
Dec 17 2025
Newsfilter
Compugen's Stock Increases Following Royalty Agreement with AstraZeneca
Dec 17 2025
SeekingAlpha
Compugen Reports Third Quarter 2025 Results
Nov 10 2025
PRnewswire
Compugen to Participate in Stifel 2025 Healthcare Conference
Nov 04 2025
PRnewswire
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Oct 27 2025
PRnewswire
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Oct 13 2025
PRnewswire
Compugen to Present Research at the Single Cell Genomics 2025 Conference
Sep 08 2025
PRnewswire
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 28 2025
PRnewswire
Compugen: Q2 Earnings Snapshot
Aug 06 2025
Yahoo Finance
Compugen Reports Second Quarter 2025 Results
Aug 06 2025
PRnewswire
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
Jul 28 2025
PRnewswire
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
Jul 21 2025
PRnewswire
RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?
Jun 24 2025
NASDAQ.COM
Show More News
